Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells

Resistance is one limitation of sorafenib in the treatment of hepatocellular carcinoma (HCC). Insulin-like growth factor-1 receptor (IGF-1R) is involved in cancer cell proliferation. To assess the potential synergistic antitumor effects of picropodophyllin (PPP), an IGF-1R inhibitor, HLF and PLC/PRL...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: TOMIZAWA, MINORU, SHINOZAKI, FUMINOBU, MOTOYOSHI, YASUFUMI, SUGIYAMA, TAKAO, YAMAMOTO, SHIGENORI, SUEISHI, MAKOTO
Materialtyp: Artigo
Språk:Inglês
Publicerad: D.A. Spandidos 2014
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186500/
https://ncbi.nlm.nih.gov/pubmed/25289088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2014.2484
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk